Inventage Lab Co., Ltd. (CEO Joohee Kim) and Curatis Co., Ltd. (CEO Seongjun Kim) announced on the 19th that they signed a supply contract worth 7 billion won to build a CDMO production line dedicated to long-acting injectables based on microfluidics technology.
With this contract, Inventage Lab’s long-acting injection platform, ‘IVL-DrugFluidic®’ technology, has entered the full-scale commercialization stage. Curatis will be responsible for producing pharmaceuticals using this technology by establishing a dedicated global-level GMP (Good Manufacturing Practice) production facility within its bioplant located in Osong, Chungcheongbuk-do.
Inventage Labs will be responsible for designing a dedicated manufacturing line within Curatis’ GMP facility, and will provide platform-based process design and customized equipment and facilities. The production line will produce clinical trial and commercial products for key pipelines currently under development, including obesity treatment, drug addiction treatment, and dementia treatment.
The two companies signed a strategic business agreement (MOU) in February of last year regarding the construction of a long-acting injection production facility, and with this contract, Inventage Lab is expected to accelerate the commercialization of its pipeline under development and its entry into the global market. Curatis is also expected to strengthen its high value-added CDMO (contract manufacturing) business capabilities by securing a GMP production facility dedicated to long-acting injections.
“This agreement is a significant milestone in the commercialization of our IVL-DrugFluidic® platform,” said Joohee Kim, CEO of Inventage Labs. “We expect Curatis to create synergy in the global market as an optimal partner with both technological and facility capabilities.”
“We invested in introducing Inventage Lab’s dedicated production facility in order to grow into a global bio platform company centered on the high value-added CDMO business,” said Kim Sung-jun, CEO of Curatis. “The dedicated facility is designed to enable expanded commercial production, and will allow us to quickly respond to the diverse demands of our global partners.”
- See more related articles
You must be logged in to post a comment.